BR0315897A - agentes antiinfecciosos - Google Patents
agentes antiinfecciososInfo
- Publication number
- BR0315897A BR0315897A BRPI0315897-7A BR0315897A BR0315897A BR 0315897 A BR0315897 A BR 0315897A BR 0315897 A BR0315897 A BR 0315897A BR 0315897 A BR0315897 A BR 0315897A
- Authority
- BR
- Brazil
- Prior art keywords
- hcv
- inhibiting
- processes
- provides
- polymerase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
AGENTES ANTIINFECCIOSOS A presente invenção proporciona um composto inibidor da polimerase do HCV tendo a fórmula (I) e uma composição compreendendo uma quantidade terapeuticamente eficaz do dito composto. A presente invenção também proporciona um método para inibir a polimerase do vírus da hepatite C (HCV), um método para inibir a duplicação viral do HCV, e um método para tratar ou prevenir a infecção por HCV. São também proporcionados processos para preparar os ditos compostos, e intermediários sintéticos empregados nos ditos processos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/285,714 US20040097492A1 (en) | 2002-11-01 | 2002-11-01 | Anti-infective agents |
US10/410,853 US20040087577A1 (en) | 2002-11-01 | 2003-04-10 | Anti-infective agents |
US10/625,121 US20040162285A1 (en) | 2002-11-01 | 2003-07-23 | Anti-infective agents |
US10/679,881 US20050075331A1 (en) | 2003-10-06 | 2003-10-06 | Anti-infective agents |
PCT/US2003/034707 WO2004041818A1 (en) | 2002-11-01 | 2003-10-31 | Anti-infective agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0315897A true BR0315897A (pt) | 2008-05-13 |
Family
ID=32314949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0315897-7A BR0315897A (pt) | 2002-11-01 | 2003-10-31 | agentes antiinfecciosos |
Country Status (8)
Country | Link |
---|---|
EP (2) | EP1560827B1 (pt) |
KR (1) | KR20050065670A (pt) |
AU (1) | AU2003291670A1 (pt) |
BR (1) | BR0315897A (pt) |
CA (1) | CA2504385C (pt) |
MX (1) | MXPA05004670A (pt) |
PL (1) | PL376823A1 (pt) |
WO (1) | WO2004041818A1 (pt) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6881741B2 (en) | 2001-06-11 | 2005-04-19 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
US7902203B2 (en) | 2002-11-01 | 2011-03-08 | Abbott Laboratories, Inc. | Anti-infective agents |
PT1569929E (pt) | 2002-12-10 | 2010-06-18 | Virochem Pharma Inc | Compostos e métodos para o tratamento ou prevenção de infecções por flavivírus |
CA2577528A1 (en) | 2004-08-23 | 2006-03-02 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
JP2008531596A (ja) * | 2005-02-25 | 2008-08-14 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Hcv感染を治療または予防するのに有用なベンゾイソチアゾール |
BRPI0611388A2 (pt) * | 2005-05-04 | 2010-09-08 | Hoffmann La Roche | compostos antivirais heterocìclicos, uso dos mesmos e composição farmacêutica |
CA2642483A1 (en) | 2006-02-17 | 2007-08-23 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
WO2008011337A1 (en) * | 2006-07-19 | 2008-01-24 | Abbott Laboratories | Hcv inhibitors |
WO2008043704A1 (en) | 2006-10-10 | 2008-04-17 | Medivir Ab | Hcv nucleoside inhibitor |
NZ576780A (en) | 2006-11-15 | 2011-12-22 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
ATE548044T1 (de) | 2007-05-04 | 2012-03-15 | Vertex Pharma | Kombinationstherapie zur behandlung von hiv- infektionen |
CA2697399C (en) | 2007-09-14 | 2016-01-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
RS51660B (en) | 2007-09-14 | 2011-10-31 | Ortho-Mcneil-Janssen Pharmaceuticals Inc. | 1`, 3`-DISUPSTITUATED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1`H- [1,4`] BIPYRIDINYL-2`-ONE |
CA2698929C (en) | 2007-09-14 | 2016-01-19 | Addex Pharma S.A. | 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones |
JP5433582B2 (ja) | 2007-11-14 | 2014-03-05 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | イミダゾ[1,2−a]ピリジン誘導体およびmGluR2受容体の正のアロステリック調節因子としてのその使用 |
EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
GB0800855D0 (en) * | 2008-01-17 | 2008-02-27 | Syngenta Ltd | Herbicidal compounds |
CA2730517A1 (en) * | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
WO2010025890A1 (en) | 2008-09-02 | 2010-03-11 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
EP2346505B1 (en) | 2008-10-16 | 2014-04-23 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
US8691813B2 (en) | 2008-11-28 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
JP2012514605A (ja) | 2009-01-07 | 2012-06-28 | サイネクシス,インコーポレーテッド | Hcvおよびhiv感染の治療への使用におけるシクロスポリン誘導体 |
AU2010220374A1 (en) | 2009-03-06 | 2011-09-01 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
EP2421831A1 (en) | 2009-04-25 | 2012-02-29 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
EP2430022B1 (en) | 2009-05-12 | 2013-11-20 | Janssen Pharmaceuticals, Inc. | 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
EP2430031B1 (en) | 2009-05-12 | 2013-04-17 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
SG176163A1 (en) * | 2009-05-20 | 2011-12-29 | Hoffmann La Roche | Heterocyclic antiviral compounds |
AU2010264802A1 (en) | 2009-06-24 | 2012-01-19 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compound |
US8389560B2 (en) | 2009-09-15 | 2013-03-05 | Taigen Biotechnology Co., Ltd. | HCV protease inhibitors |
EP2480533A1 (en) | 2009-09-21 | 2012-08-01 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
WO2011057989A1 (en) * | 2009-11-11 | 2011-05-19 | Basf Se | Heterocyclic compounds having herbicidal action |
NZ599373A (en) | 2009-11-14 | 2013-04-26 | Hoffmann La Roche | Biomarkers for predicting rapid response to hcv treatment |
WO2011061243A1 (en) | 2009-11-21 | 2011-05-26 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
MX2012005703A (es) | 2009-12-02 | 2012-06-12 | Hoffmann La Roche | Biomarcadores para pronosticar una respuesta prolongada al tratamiento contra el vhc. |
WO2012062750A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
AU2011328203B2 (en) | 2010-11-08 | 2015-03-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
EP2643320B1 (en) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
US9139534B2 (en) | 2011-04-22 | 2015-09-22 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
RU2534613C2 (ru) | 2013-03-22 | 2014-11-27 | Александр Васильевич Иващенко | Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
LT3431106T (lt) | 2014-01-21 | 2021-02-10 | Janssen Pharmaceutica Nv | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
KR20220038826A (ko) | 2014-01-21 | 2022-03-29 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
CN106810557B (zh) * | 2015-11-27 | 2021-05-04 | 南京圣和药物研发有限公司 | 杂环化合物及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1292310A1 (en) * | 2000-05-10 | 2003-03-19 | SmithKline Beecham Corporation | Novel anti-infectives |
AR036081A1 (es) * | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
WO2003059356A2 (en) * | 2001-10-30 | 2003-07-24 | Smithkline Beecham Corporation | Novel anti-infectives |
-
2003
- 2003-10-31 BR BRPI0315897-7A patent/BR0315897A/pt not_active IP Right Cessation
- 2003-10-31 EP EP03768559A patent/EP1560827B1/en not_active Expired - Lifetime
- 2003-10-31 MX MXPA05004670A patent/MXPA05004670A/es active IP Right Grant
- 2003-10-31 KR KR1020057007790A patent/KR20050065670A/ko not_active Application Discontinuation
- 2003-10-31 EP EP10185841A patent/EP2361913A1/en not_active Withdrawn
- 2003-10-31 WO PCT/US2003/034707 patent/WO2004041818A1/en active Search and Examination
- 2003-10-31 CA CA2504385A patent/CA2504385C/en not_active Expired - Fee Related
- 2003-10-31 PL PL376823A patent/PL376823A1/pl unknown
- 2003-10-31 AU AU2003291670A patent/AU2003291670A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1560827B1 (en) | 2010-12-29 |
WO2004041818A1 (en) | 2004-05-21 |
KR20050065670A (ko) | 2005-06-29 |
CA2504385C (en) | 2012-12-18 |
EP2361913A8 (en) | 2012-04-18 |
MXPA05004670A (es) | 2005-08-18 |
AU2003291670A1 (en) | 2004-06-07 |
CA2504385A1 (en) | 2004-05-21 |
EP2361913A1 (en) | 2011-08-31 |
EP1560827A1 (en) | 2005-08-10 |
PL376823A1 (pl) | 2006-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0315897A (pt) | agentes antiinfecciosos | |
BR0305259A (pt) | Inibidores de hcv ns5b polimerase | |
BR0309581A (pt) | Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c | |
BR0305426A (pt) | Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos | |
BRPI0415883A (pt) | compostos e composições de nucleosìdeo para o tratamento de infecções virais | |
BRPI0514591A (pt) | compostos antivirais heterocìclicos | |
BRPI0515596A (pt) | composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero | |
BR0206614A (pt) | Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto | |
GEP20104960B (en) | USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN | |
CL2004001161A1 (es) | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. | |
WO2003105770A3 (en) | CARBOCYCLIC NUCLEOSIDE DERIVATIVES FOR USE AS VIRAL RNA-DEPENDENT RNA POLYMERASE INHIBITORS | |
ES2160046A1 (es) | Derivados pentapeptidicos. | |
DE60143672D1 (de) | Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation | |
BR9908004A (pt) | Composto, composição e método para prevençãoou supressão de uma infecção viral | |
ID27787A (id) | Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan | |
WO2004009020A3 (en) | Pyrrolopyrimidine thionucleoside analogs as antivirals | |
BR0306931A (pt) | Peptìdeos como inibidores de protease serina-ns3 do vìrus da hepatite c | |
BRPI0514425A (pt) | inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos | |
BRPI0418251B8 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
BR0115447A (pt) | Inibidores de tripeptìdeo de hepatite c | |
TR200300544T1 (tr) | Erimiş siklik bileşimler ve tıbbi kullanımları | |
WO2004000858A3 (en) | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | |
WO2004003138A3 (en) | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | |
WO2009069095A3 (en) | Antiviral nucleoside compounds | |
BR0313755A (pt) | Composto, métodos para inibir a replicação ou proliferação de um vìrion da hepatite c e para tratar ou prevenir uma infecção por hcv, e, composição |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |